Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies

Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
• Source: Shutterstock

Adaptimmune Therapeutics plc has a powerful new partner in Roche Holding AG’s Genentech for its allogeneic T-cell therapy program, based on Adaptimmune’s induced pluripotent stem cell (iPSC)-derived platform. The deal gives the biotech a leg up in a race that has lately attracted a number of large biopharma industry players, but also marks a significant vote of confidence in Adaptimmune’s programs and for cell therapies in solid tumors overall.

Oxfordshire, UK-based Adaptimmune said 7 September that it had partnered with Genentech to develop and commercialize off-the-shelf therapies in up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.